Skip to main content

Table 5 Added predictive value of biomarkers over already known predictors for mean yearly radiographic progression rate over 5 years of treatment

From: The relation between cartilage biomarkers (C2C, C1,2C, CS846, and CPII) and the long-term outcome of rheumatoid arthritis patients within the CAMERA trial

Item B 95% CI Standardized beta P R 2
Intercept 0.54 0.12 to 0.96   0.013  
Treatment strategy 0.13 -0.16 to 0.43 0.08 0.375 0.000
RF positive 0.29 -0.02 to 0.60 0.15 0.063 0.029
Baseline joint damage 0.09 0.06 to 0.13 0.44 0.000 0.211
EULAR good responsea -0.36 -0.78 to 0.07 -0.20 0.100  
EULAR moderate responsea -0.13 -0.52 to 0.27 -0.07 0.534 0.229
C1,2C change from 1 yr to baseline -1.11 -1.87 to -0.36 -0.24 0.004 0.283
  1. aEULAR nonresponse was used as reference category. 95% CI, 95% confidence interval; RF, rheumatoid factor.